➤ FDA clears device for MGD treatment ➤ Significant investments made in whole-eye transplant research ➤ Enrollment completed early in Phase 3 trial for novel glaucoma drop ➤ Studies make progress with gene and mRNA-based therapies for retinal conditions ➤ ASCRS news and events
➤ 52-week Phase 3 data published for cyclosporine, 0.1% ➤ First patient enrolled in Phase 3 trial assessing new treatment for MGD ➤ Geographic atrophy treatment trial advances to highest dose ➤ New dataset added to support various areas of research and development ➤ ASCRS news and events
➤ Positive topline results in Phase 2a trial for treatment of MGD in patients with Demodex ➤ First patient visit in Phase 2b trial evaluating anti-TNFα for dry eye disease ➤ Smart contact lens makes progress ➤ Asset transition ➤ ASCRS news and events
➤ FDA approves dry eye drop targeting tear evaporation ➤ Topline results from Phase 3 trial of eye drops for DME ➤ Investigational intravitreal gene therapy program introduced for geographic atrophy ➤ Phase 1 study for periocular drug for wet AMD and DME begins ➤ Commercial rights for uveitis treatment acquired ➤ ASCRS news and events
➤ FDA approves AI-based diabetic retinopathy screener ➤ FDA accepts NDA for Demodex treatment ➤ Phase 2b results for MGD therapy ➤ Phase 1/2 trial evaluates investigational TED treatment ➤ Phase 1 clinical trial to study synthetic cannabinoid derivative for glaucoma ➤ OCT company rebrands ➤ ASCRS news and events
➤ FDA approves device to treat MGD ➤ Standalone MIGS device trial begins ➤ Topline results for novel dry eye candidate ➤ Orphan drug designation granted for topical LHON treatment ➤ Positive safety results in Phase 1/2a trial for investigational treatment of wet AMD ➤ Updates on two investigational RNA therapies ➤ ASCRS news and events